Bacterin International Holdings Inc. is the developer of revolutionary bone graft material and antimicrobial coatings for a number of medical applications. The company’s proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold and promote bone and other tissue growth.
The company announced recently that it is commencing distribution of Bacterin’s third human acellular biological scaffold, hMatrix, an acellular dermal scaffold. It is an acellular matrix processed from donated human dermal tissue that is used to replace damaged tissue or repair, reinforce or support soft tissue defects. hMatrix retains the natural structure of dermis to promote cellular growth, tissue vascularization and regeneration.
In line with Bacterin’s focus on providing safe products, hMatrix will be distributed as a sterile product. The company initially intends to market hMatrix for homologous use indications, including abdominal wall repair, breast reconstruction, and for wound covering. The wound covering sector itself is estimated by the company to have a market size exceeding $2.5 billion in the United States alone.
Bacterin’s CEO and chairman, Guy Cook, is excited by the outlook for the new product. He said, “We have received a great deal of interest [in hMatrix], and are very optimistic of its revenue potential.” For further information on Bacterin and its line of biologic products, please visit the company’s website at www.bacterin.com.